RED
BANK, N.J., Feb. 23,
2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:
PRVB) (the "Company"), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated diseases, today
announced that it will report its fourth quarter and full year
2022 financial results on Thursday, March 16, 2023, before the
opening of the U.S. financial markets. Subsequently, at 8:00
am E.T., the company will host a conference call to discuss its
financial results and provide a corporate update.
To access the call, please dial 1-888-347-7861 (domestic) or
1-412-902-4247 (international) ten minutes prior to the start time
and ask to be connected to the "Provention Bio Call." An audio
webcast will also be available on the "Events and Webcasts" page of
the Investors section of the Company's
website, www.proventionbio.com. An archived webcast will be
available on the Company's website approximately two hours after
the conference call.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a commercial-stage
biopharmaceutical company focused on advancing the development and
commercialization of investigational therapies that may intercept
and prevent debilitating and life-threatening immune-mediated
diseases. The Company's pipeline includes clinical-stage product
candidates that have demonstrated in pre-clinical or clinical
studies proof-of-mechanism and/or proof-of-concept in autoimmune
diseases, including T1D, celiac disease and lupus. Visit
www.ProventionBio.com for more information and follow us on
Twitter: @ProventionBio.
Internet Posting of Information
Provention Bio, Inc. uses its
website, www.proventionbio.com, as a means of disclosing
material nonpublic information and for complying with its
disclosure obligations under Regulation F.D. Such disclosures will
be included on the Company's website in the "News" section.
Accordingly, investors should monitor this portion of the Company's
website, in addition to following its press releases, SEC filings
and public conference calls and webcasts.
Forward Looking Statements
Certain statements in this press release are forward-looking,
including but not limited to, statements relating to the Company's
fourth quarter and full year 2022 financial results. These
statements may be identified by the use of forward-looking words
such as "will" and "may," among others. These forward-looking
statements are based on the Company's current expectations and
actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These factors
include, but are not limited to, failure to maintain FDA approval
for TZIELD; the commercial launch in the US for TZIELD may not be
successful in part or at all for various reasons including the
actual market size and drug supply needed may not be consistent
with the company's expectations and its commercial plans; the
degree to which TZIELD is accepted by patients and prescribed by
physicians; the efficiency of our manufacturing, sales,
distribution and specialty pharmacy network in getting TZIELD to
the market and future economic, competitive, reimbursement and
regulatory conditions that could negatively impact the commercial
launch of TZIELD; the post-marketing commitment studies for TZIELD
may not yield data consistent with prior results; we may not be
able to execute on our business plans including meeting our
expected or planned regulatory milestones and timelines, clinical
development plans and successfully bringing our product candidates
to market, for various reasons, including factors outside of the
Company's control, such as possible limitations of Company
financial and other resources, competition, manufacturing
limitations that may not be anticipated or resolved for in a timely
manner or at all, and regulatory, court or agency decisions, such
as decisions by the United States Patent and Trademark Office with
respect to patents that cover our product candidates, the potential
for noncompliance with FDA regulations; the potential impacts of
COVID-19 on our business and financial results; changes in law,
regulations, or interpretations and enforcement of regulatory
guidance; uncertainties of patent protection and litigation;
competition and the risks listed under "Risk Factors" in the
Company's quarterly report on Form 10-Q for the quarter
ended September 30, 2022 and any subsequent filings with
the Securities and Exchange Commission. As with any pharmaceutical
under development, there are significant risks in the development,
regulatory approval, and commercialization of new products.
Provention does not undertake an obligation to update or revise any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
applicable law. The information set forth herein speaks only as of
the date hereof.
Investor Contact:
Kristen
Kelleher, Senior Manager, Investor Relations
kkelleher@proventionbio.com
Media Contact:
Kaelan
Hollon, VP of Communications
khollon@proventionbio.com
202-421-4921
View original content to download
multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-16-2023-301754445.html
SOURCE Provention Bio, Inc.